Members of President-elect Donald Trump’s economic team are reportedly discussing a plan to gradually increase tariffs, according to a report from Bloomberg, citing people familiar with the matter.

The company reported revenue of $199.3 million for the third quarter ended October 31, 2024, a 24.6% increase from $160 million in the same period last year. However, ServiceTitan’s adjusted loss per ...

Investing.com -- Shares of Blueprint Medicines (NASDAQ: BPMC) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic ...

Castle Biosciences ended the year with strong cash reserves, expecting approximately $120 million in cash and cash equivalents and an estimated $173 million in marketable investment securities. These ...

Despite the rising interest in other options such as BRICS currencies, Bitcoin, and gold, the USD continues to be the ...

Investing.com -- Shares of GoodRx (NASDAQ:GDRX) tumbled 7% following the announcement that CFO Karsten Voermann is resigning this week for personal reasons. The digital health care company revealed ...

Starbucks (NASDAQ: SBUX) has initiated a new code of conduct this month, aiming to enhance the safety and experience for both ...

The analysts also underscored that geopolitical events, including sanctions, tariffs, and international relations, could profoundly influence oil supply and demand balances over the next 18 months.

Inspire Medical (TASE: PMCN )’s fourth quarter revenue represents a roughly 25% increase compared to the same quarter of the previous year, while the anticipated full-year 2024 revenue of $802.6 ...

On Monday, Macquarie strategists projected an increase in US crude inventories and a significant build in product stocks for ...

Despite its pivotal role in the growth of smartphones and energy-efficient data center chips, Arm’s revenue has remained ...

Walmsley stated that GSK’s renewed focus on oncology is a strategic move to expand its specialty medicines portfolio. The company has plans to advance the IDRx drug to late-stage trials within the ...